✓
Open
17 Dec 2004
✓
Close
23 Dec 2004
3
Allotment
—
✓
Listing
Fri, Jan 14, 2005
Price Band
₹220 to ₹245
Issue Size
30,00,000 shares (agg. up to ₹74 Cr)
Listing Date
Fri, Jan 14, 2005
✦ AI Insight
Live Subscription
| Category | Subscription (times) |
|---|---|
| Total | 60.74x |
Restated Financials (₹ Cr.)
| Period Ended | 31 Mar 2004 | 31 Mar 2003 | 31 Mar 2002 |
|---|---|---|---|
| Assets | 149.66 | 127.01 | 118.71 |
| Total Income | 177.61 | 146.53 | 132.12 |
| Profit After Tax | 21.26 | 14.67 | 16.55 |
| EBITDA | 3.56 | 2.45 | 2.28 |
| NET Worth | 87.64 | 71.12 | 71.45 |
| Reserves and Surplus | 79.19 | 62.91 | 62.94 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Dishman Pharmaceuticals & Chemicals Ltd. | Mainboard | ₹60.09 Cr | ₹175 | 12.64 | ₹541.25 | +209.29% | (+0.00%) |
| Biocon Ltd. | Mainboard | ₹315.00 Cr | ₹315 | 80.29 | ₹484.05 | +53.67% | ₹440.70 (+1.39%) |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Investment in subsidiary company, Indoco Healthcare Limited (IHL) for setting up of its plant to manufacture ointments, toothpaste, tablet, cephalosporin and meet UK MHRA, WHO and South Africa MCC standards | 25.79 |
| 2 | Setting up of plant to manufacture APIs | 22.00 |
| 3 | Setting-up of research and development Centre for APIs | 15.86 |
| 4 | Repayment of unsecured loan taken for acquisition of brand | 9.37 |
| 5 | Repayment of loan taken for acquisition of Office Premises | 5.21 |
| 6 | Issue expense | 5.00 |
| Total | 83.23 |
About Indoco Remedies IPO
Indoco Remedies Ltd. is a Mumbai-based, fully integrated pharmaceutical company that manufactures and markets finished dosage formulations and Active Pharmaceutical Ingredients (APIs) globally. The company operates 9 manufacturing facilities and exports to over 55 countries. Indoco specialises in a broad range of therapeutic categories, including gastroenterology, dentistry, respiratory, diabetology, and women's health. The company's key products include Cyclopam (antispasmodic), Febrex Plus (cough-and-cold syrup), Cital (urinary alkalizer), and Dentogel. Indoco maintains international accreditations, including US FDA and UK MHRA, and holds an 85% stake in Florida Pharmaceutical Products (FPP) in the USA. Indoco divested its ophthalmic business operations in identified emerging markets to Sunways in a strategic slump sale, allowing the company to refocus its core therapeutic operations. The company generates over 109 million prescriptions annually from over 249,000 doctors nationwide. + Read More
Contact Details
Indoco Remedies Ltd. AddressIndoco House, 166C.S.T. RoadSantacruz (East)Mumbai, Maharashtra, 400098ipo@indoco.comVisit Website